This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

No abstract

IntroductionGlucagon-like peptide-1 (GLP-1) is an endogenous peptide that stimulates insulin secretion and decreases glucagon secretion. The use of GLP-1 receptor agonists (GLP-1RA) showed efficacy reducing the weight and glucose levels in patients with and without type 2 diabetes. This effect was also associated with a decreased risk of major cardiovascular events.ObjectivesOur aim is to review the role of GLP-1RA in psychiatric patients at cardio-metabolic risk due to antipsychotics treatment.Methods We reviewed articles published in PubMed using the keywords: “GLP-1” “glucagon like peptide” “antipsychotics” and “psychiatry”.ResultsThe number need to treat (NNT) to achieve clinical meaningful weight loss was 3.8. GLP-1RA treatment was also associated with greater reductions in body mass index, fasting glucose, HbA1c and visceral fat. This effect is true for antipsychotic treatment in general and for those on clozapine and olanzapine in particular. Overall, the GLP-1RA are well tolerated with nausea being the most common related adverse effect. Other variables such as age, sex, psychosis severity, nausea or any adverse drug reaction did not affect the weight loss.ConclusionsStudies showed a promising role in the management of antipsychotics induced weight gain, particularly in clozapine and olanzapine treated patients. Although these promising results, the route of administration, with a daily or weekly subcutaneous injection, and the GLP-1RA associated financial costs, can be viewed as important factors which can limit the wide use of this type of treatment in psychiatric patients.DisclosureNo significant relationships.

Regular physical activity -aerobic, strength exercises and yoga -have been shown to improve metabolic syndrome parameters, cognitive deficits, positive and negative symptoms, quality of life and global functioning 1 .

Objectives:Characterize a subgroup of Parkinson's Disease (PD) patients with isolated delusions (ID). Background:PD patients are particularly prone to develop psychotic symptoms due to the disease itself and to dopaminergic treatments. Visual hallucinations, with or without delusions, are the classic manifestation, mainly associated with disease progression and cognitive deterioration. However, a distinct subset may develop ID. Materials and Methods:PD patients followed by the authors between 01.01.2014 and 31.01.2018 at a movement disorders clinic were identified using the ICD9 code 3320. Charts were retrospectively reviewed to identify patients with ID. Neurological and Psychiatric interviews were performed, including MDS-UPDR, MoCA, NPI, SCOPA-PC, HAM-D.